Almirall, S.A. is a Spanish pharmaceutical company headquartered in Barcelona and founded in 1944. It focuses on the development, production, and marketing of medical dermatology treatments for conditions including atopic dermatitis, psoriasis, acne, and actinic keratosis.
The company operates in more than 100 countries with around 2,100 employees and maintains research, chemical, and pharmaceutical manufacturing facilities. It is publicly listed on the Spanish stock exchange and remains under family influence following a generational leadership transition in 2022.
Almirall holds European rights for certain products, such as EBGLYSS (lebrikizumab), while partners manage commercialization elsewhere. Its activities also encompass related chemical and biotechnological products.
Official website: almirall.com
To provide comprehensive coverage, we aggregate data and news under the name Almirall, encompassing the following company names, divisions, and related entities:
Almirall SA.
This list encompasses current and former names, alternate names, and key divisions associated with Almirall, ensuring you can easily find all relevant information under a single, unified profile.
